論文

査読有り 国際誌
2017年6月

CHOP or THP-COP regimens in the treatment of newly diagnosed peripheral T-cell lymphoma, not otherwise specified: a comparison of doxorubicin and pirarubicin.

Hematological oncology
  • Yuhei Shibata
  • ,
  • Takeshi Hara
  • ,
  • Senji Kasahara
  • ,
  • Toshiki Yamada
  • ,
  • Michio Sawada
  • ,
  • Ryoko Mabuchi
  • ,
  • Takuro Matsumoto
  • ,
  • Nobuhiko Nakamura
  • ,
  • Hiroshi Nakamura
  • ,
  • Soranobu Ninomiya
  • ,
  • Junichi Kitagawa
  • ,
  • Nobuhiro Kanemura
  • ,
  • Yusuke Kito
  • ,
  • Naoe Goto
  • ,
  • Tatsuhiko Miyazaki
  • ,
  • Tsuyoshi Takami
  • ,
  • Tamotsu Takeuchi
  • ,
  • Masahito Shimizu
  • ,
  • Hisashi Tsurumi

35
2
開始ページ
163
終了ページ
171
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1002/hon.2262
出版者・発行元
WILEY

The CHOP regimen consisting of cyclophosphamide, doxorubicin (DOX), vincristine and prednisolone has been the most used regimen for peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS). Pirarubicin [tetrahydropyranyladriamycin (THP)], a derivative of DOX, is an anthracycline with reportedly less cardiotoxicity than DOX. Here, we confirmed the efficacy of THP-COP using THP instead of DOX in the treatment of PTCL-NOS. The study protocol employed a retrospective, consecutive entry design. We retrospectively analysed 56 patients with PTCL-NOS who had received THP-COP or CHOP. These regimens were performed every 21 days. Twenty-nine patients received THP-COP, and 27 received CHOP. There were no significant differences in known prognostic factors, including in the International Prognostic Index (IPI) and the prognostic index for T-cell lymphoma (PIT), between the two groups. Complete remission rates in patients with THP-COP and CHOP were 52% in both groups; the 3-year overall survival (OS) rates were 67% and 52% (p = 0.074), and the 3-year progression-free survival (PFS) rates were 51% and 29% (p = 0.070), respectively. In patients with low IPI (low or low-intermediate), THP-COP had significantly better 3-year OS (100% vs. 64%; p < 0.001) and 3-year PFS (75% vs. 33%; p < 0.05) than CHOP. Similar differences between THP-COP and CHOP were observed in patients with a low PIT (groups 1 or 2). Our study showed that THP-COP produced results equivalent to CHOP regarding efficacy and safety in patients with PTCL-NOS. In patients with low IPI or PIT, THP-COP resulted in significantly better prognosis. Copyright © 2015 John Wiley & Sons, Ltd.

Web of Science ® 被引用回数 : 4

リンク情報
DOI
https://doi.org/10.1002/hon.2262
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/26449182
Web of Science
https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=JSTA_CEL&SrcApp=J_Gate_JST&DestLinkType=FullRecord&KeyUT=WOS:000403677200004&DestApp=WOS_CPL

エクスポート
BibTeX RIS